Prostate cancer
Conditions
Interventions
Androgen deprivation therapy + novel hormonal therapy + all-site radiation therapy + docetaxel group (Androgen deprivation therapy + novel hormonal therapy + all-site radiation therapy + docetaxel che
Androgen deprivation therapy + novel hormonal therapy + all-site radiation therapy group (Androgen deprivation therapy + novel hormonal therapy + all-site radiation therapy):None
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Initial puncture pathology or postoperative pathology confirms GS 9-10 points. 2.Initial diagnosis or postoperative treatment without adjuvant ADT with complete imaging confirming the occurrence of distant metastases. 3.The treatment regimen was radiotherapy + ADT ± novel hormonal therapy ± chemotherapy. The radiotherapy regimen included all-site radiotherapy for oligometastatic subjects ( 12 months. 5.Age >= 18 years. 6.KPS >= 80. 7.White blood cells >= 3.5 x 10^9/l, neutrophils >= 1.5 x 10^9/l, platelets = 100.0 x 10^9/l, haemoglobin >= 90g/l. 8.Subject informed consent.
Exclusion criteria
Exclusion criteria: 1.Previous history of malignant tumors (except for tumors that have been cured for more than 5 years). 2.Previous abdominal radiotherapy. 3.Weight loss >10% in 6 months. 4.Persons with pre-existing or coexisting hemorrhagic disorders. 5.Presence of active infection. 6.Clinically significant cardiac disease (eg. Medically controlled hypertension, unstable colic, New York Heart Association (NYHA) class = II congestive heart failure, unstable symptomatic arrhythmia, or class = II peripheral vascular disease). 7.Psychological, family, social, and other factors leading to uninformed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;radiographic Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate Cancer-Specific Survival;PSA progression-free survival;time to new anti-cancer treatment;castration-resistant prostate cancer (CRPC)-free survival;skeletal event-free survival;urinary symptom deterioration-free survival;Functional Assessment of Prostate Cancer Therapy; | — |
Countries
China
Contacts
Public ContactXianshu Gao
Peking University First Hospital
Outcome results
None listed